ERBB2 and breast cancer: Subgroup analyses showed that low ZNF385B expression significantly affected the OS and RFS in many BC subtypes such as infiltrating ductal carcinoma, ER-negative BC, ER-positive BC, PR-negative BC, HER-2-negative BC, and HER-2-positive BC, and its low expression showed worse prognosis in those patients.